Steba’s Tookad: US FDA Panel To Weigh Novel Endpoints, Missing Data And Toxicities

 
• By Sue Sutter
  
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra
Steba is seeking accelerated approval for low-risk, early-stage prostate cancer, but US FDA may want more data. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers